1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Introduction
2.2. Define: Research Objective
2.3. Determine: Research Design
2.4. Prepare: Research Instrument
2.5. Collect: Data Source
2.6. Analyze: Data Interpretation
2.7. Formulate: Data Verification
2.8. Publish: Research Report
2.9. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19

6. Next Generation Cancer Diagnostics Market, by Technology
6.1. Introduction
6.2. DNA Microarrays
6.3. Lab-on- a- chip & Reverse Transcriptase-PCR
6.4. Next Generation Sequencing
6.5. Protein Microarrays
6.6. qPCR & Multiplexing

7. Next Generation Cancer Diagnostics Market, by Cancer Type
7.1. Introduction
7.2. Breast Cancer
7.3. Cervical Cancer
7.4. Colorectal Cancer
7.5. Lung Cancer

8. Next Generation Cancer Diagnostics Market, by Function
8.1. Introduction
8.2. Cancer Screening
8.3. Companion Diagnostics
8.4. Prognostics
8.5. Risk Analysis
8.6. Therapeutic Monitoring

9. Next Generation Cancer Diagnostics Market, by Application
9.1. Introduction
9.2. Biomarker Development
9.3. CTC Analysis
9.4. Epigenetic Analysis
9.5. Genetic Analysis
9.6. Proteomic Analysis

10. California Next Generation Cancer Diagnostics Market

11. Florida Next Generation Cancer Diagnostics Market

12. Illinois Next Generation Cancer Diagnostics Market

13. New York Next Generation Cancer Diagnostics Market

14. Ohio Next Generation Cancer Diagnostics Market

15. Pennsylvania Next Generation Cancer Diagnostics Market

16. Texas Next Generation Cancer Diagnostics Market

17. Competitive Landscape
17.1. FPNV Positioning Matrix
17.1.1. Quadrants
17.1.2. Business Strategy
17.1.3. Product Satisfaction
17.2. Market Ranking Analysis
17.3. Market Share Analysis, By Key Player
17.4. Competitive Scenario
17.4.1. Merger & Acquisition
17.4.2. Agreement, Collaboration, & Partnership
17.4.3. New Product Launch & Enhancement
17.4.4. Investment & Funding
17.4.5. Award, Recognition, & Expansion

18. Company Usability Profiles
18.1. Abbott Laboratories
18.2. Adaptive Biotechnologies Inc.
18.3. Agendia Nv
18.4. Agilent Technologies, Inc
18.5. Akadeum Life Sciences
18.6. Almac Group
18.7. Ambry Genetics
18.8. Becton, Dickinson And Co.
18.9. Biological Dynamics Inc.
18.10. Castle Biosciences Inc.
18.11. Danaher Corporation
18.12. Exosome Diagnostics, Inc.
18.13. F. Hoffmann-La Roche Ltd
18.14. GE Healthcare
18.15. Genomic Health, Inc.
18.16. Hologic, Inc
18.17. Illumina, Inc.
18.18. Janssen Global Services, LLC
18.19. Koninklijke Philips N.V.
18.20. Myriad Genetics, Inc.
18.21. Novartis AG
18.22. Opko Health, Inc.
18.23. Perkin Elmer, Inc.
18.24. Qiagen N.V.
18.25. Sysmex Corporation
18.26. Thermo Fisher Scientific, Inc.

19. Appendix
19.1. Discussion Guide
19.2. License & Pricing

List of Figures

FIGURE 1. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET: MARKET DYNAMICS
FIGURE 3. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2020 VS 2027 (%)
FIGURE 4. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2020 VS 2027 (USD MILLION)
FIGURE 5. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2027
FIGURE 6. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, 2018-2027 (USD MILLION)
FIGURE 7. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 8. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR, 2018-2027 (USD MILLION)
FIGURE 9. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 10. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2027 (USD MILLION)
FIGURE 11. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 12. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, 2018-2027 (USD MILLION)
FIGURE 13. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 14. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, 2018-2027 (USD MILLION)
FIGURE 15. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 16. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2020 VS 2027 (%)
FIGURE 17. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2020 VS 2027 (USD MILLION)
FIGURE 18. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2027
FIGURE 19. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, 2018-2027 (USD MILLION)
FIGURE 20. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 21. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, 2018-2027 (USD MILLION)
FIGURE 22. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 23. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, 2018-2027 (USD MILLION)
FIGURE 24. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 25. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, 2018-2027 (USD MILLION)
FIGURE 26. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 27. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2020 VS 2027 (%)
FIGURE 28. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2020 VS 2027 (USD MILLION)
FIGURE 29. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2027
FIGURE 30. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, 2018-2027 (USD MILLION)
FIGURE 31. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 32. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2027 (USD MILLION)
FIGURE 33. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 34. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, 2018-2027 (USD MILLION)
FIGURE 35. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 36. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ANALYSIS, 2018-2027 (USD MILLION)
FIGURE 37. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ANALYSIS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 38. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2027 (USD MILLION)
FIGURE 39. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 40. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2020 VS 2027 (%)
FIGURE 41. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2020 VS 2027 (USD MILLION)
FIGURE 42. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2027
FIGURE 43. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, 2018-2027 (USD MILLION)
FIGURE 44. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 45. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, 2018-2027 (USD MILLION)
FIGURE 46. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 47. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, 2018-2027 (USD MILLION)
FIGURE 48. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 49. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, 2018-2027 (USD MILLION)
FIGURE 50. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 51. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, 2018-2027 (USD MILLION)
FIGURE 52. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 53. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX
FIGURE 54. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 55. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET, BY TYPE

List of Tables

TABLE 1. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2027 (USD MILLION)
TABLE 4. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY STATE, 2018-2027 (USD MILLION)
TABLE 5. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR, BY STATE, 2018-2027 (USD MILLION)
TABLE 6. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY STATE, 2018-2027 (USD MILLION)
TABLE 7. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY STATE, 2018-2027 (USD MILLION)
TABLE 8. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY STATE, 2018-2027 (USD MILLION)
TABLE 9. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2027 (USD MILLION)
TABLE 10. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY STATE, 2018-2027 (USD MILLION)
TABLE 11. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY STATE, 2018-2027 (USD MILLION)
TABLE 12. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY STATE, 2018-2027 (USD MILLION)
TABLE 13. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY STATE, 2018-2027 (USD MILLION)
TABLE 14. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2027 (USD MILLION)
TABLE 15. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY STATE, 2018-2027 (USD MILLION)
TABLE 16. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY STATE, 2018-2027 (USD MILLION)
TABLE 17. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY STATE, 2018-2027 (USD MILLION)
TABLE 18. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ANALYSIS, BY STATE, 2018-2027 (USD MILLION)
TABLE 19. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY STATE, 2018-2027 (USD MILLION)
TABLE 20. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2027 (USD MILLION)
TABLE 21. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY STATE, 2018-2027 (USD MILLION)
TABLE 22. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY STATE, 2018-2027 (USD MILLION)
TABLE 23. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY STATE, 2018-2027 (USD MILLION)
TABLE 24. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY STATE, 2018-2027 (USD MILLION)
TABLE 25. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY STATE, 2018-2027 (USD MILLION)
TABLE 26. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET: SCORES
TABLE 27. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET: BUSINESS STRATEGY
TABLE 28. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET: PRODUCT SATISFACTION
TABLE 29. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET: RANKING
TABLE 30. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 31. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET: MERGER & ACQUISITION
TABLE 32. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 33. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 34. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET: INVESTMENT & FUNDING
TABLE 35. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 36. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET: LICENSE & PRICING

Companies Mentioned

Abbott Laboratories
Adaptive Biotechnologies Inc.
Agendia Nv
Agilent Technologies, Inc
Akadeum Life Sciences
Almac Group
Ambry Genetics
Becton, Dickinson And Co.
Biological Dynamics Inc.
Castle Biosciences Inc.
Danaher Corporation
Exosome Diagnostics, Inc.
F. Hoffmann-La Roche Ltd
GE Healthcare
Genomic Health, Inc.
Hologic, Inc
Illumina, Inc.
Janssen Global Services, LLC
Koninklijke Philips N.V.
Myriad Genetics, Inc.
Novartis AG
Opko Health, Inc.
Perkin Elmer, Inc.
Qiagen N.V.
Sysmex Corporation
Thermo Fisher Scientific, Inc.